Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
8/29/2024 | $131.00 → $159.00 | Neutral → Overweight | Piper Sandler | |
4/24/2024 | $140.00 → $170.00 | Equal Weight → Overweight | Wells Fargo | |
3/26/2024 | $22.00 | Buy | Guggenheim | |
3/19/2024 | $30.00 | Buy | H.C. Wainwright | |
3/7/2024 | $16.00 | Buy | Citigroup | |
1/2/2024 | $14.00 | Equal Weight → Overweight | Wells Fargo | |
12/13/2023 | $127.00 | Neutral | Citigroup | |
12/12/2023 | $136.00 | Buy | Deutsche Bank |
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc. "Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurothe
Board of Directors appoints Kyle Gano, Ph.D., Chief Business Development and Strategy Officer, as CEO-elect, effective October 11, 2024 Kevin Gorman, Ph.D., to continue to serve on the Neurocrine Board of Directors SAN DIEGO, May 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role. Dr. Gano will also join the Company's Board of Directors at that time, and Dr. Gorman will continue to serve on the Neurocrine Board.
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business
Piper Sandler upgraded Neurocrine Biosciences from Neutral to Overweight and set a new price target of $159.00 from $131.00 previously
Wells Fargo upgraded Neurocrine Biosciences from Equal Weight to Overweight and set a new price target of $170.00 from $140.00 previously
Guggenheim initiated coverage of Voyager Therapeutics with a rating of Buy and set a new price target of $22.00
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and maintains $155 price target.
Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Hold.
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe once-daily 20 mg dose efficacy, safety and tolerability Phase 2 results support advancement to Phase 3 in schizophrenia in early 2025The once-daily 20 mg dose met the primary endpoint, demonstrating a statistically significant 7.5-point improvement (p=0.011, 0.61 effect size) in the PANSS total score compared to placebo at week 6 with an 18.2-point PANSS total score improvement from baselineThe once-daily 20 mg dose met additional endpoints, demonstrating statistically significant improvements in Clinica
The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 with an 18.2-Point PANSS Total Score Improvement from BaselineThe Once-Daily 20 mg Dose Met Additional Endpoints, Demonstrating Statistically Significant Improvements in Clinical Global Impression of Severity Scale and Marder Factor Score Positive Symptom Change and Negative Symptom ChangeNBI-'568 Was Generally Safe and Well Tolerated at All Doses StudiedThe Once-Daily 20 mg Dose Efficacy, Safety and Tolerability Phase 2 Results Support Advancement to Phase 3 in Schizophrenia in Early 2025Company
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer's disease - - Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND meeting for SOD1 ALS development candidate - - Appointed strategic financial leader Nathan Jorgensen, Ph.D., as Chief Financial Officer - - Strong cash position of $371 million as of June 30, 2024, expected to provide runway through multiple clinical data readouts into 2027 - LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology comp
8-K - Voyager Therapeutics, Inc. (0001640266) (Filer)
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
S-8 - Voyager Therapeutics, Inc. (0001640266) (Filer)
LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences, Inc. has selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease. The candidate leverages an intravenously administered, blood-brain barrier-penetrant, novel capsid derived from Voyager's TRACER™ capsid discovery platform. Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the four
Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with SchizophreniaResults Confounded by Variability in Cognition Measures Across Population Studied and Potential Imbalance in Baseline Characteristics of Enrolled SubjectsNeurocrine Biosciences to Focus Resources on Phase 3 Clinical Development of NBI-1117568 for Schizophrenia and NBI-1065845 for Major Depressive DisorderSAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that its ERUDITE™ Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential
SAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m. Eastern Time on Tuesday, September 17, 2024. Chief Business Development and Strategy Officer and CEO-elect Kyle Gano, Chief Financial Officer Matt Abernethy, and Vice-President of Investor Relations Todd Tushla will present at the conference. The live presentation will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be a